Outlook Therapeutics News

Buy Rating Justified by Outlook Therapeutics' Advancements and Market Prospects

TipRanksMay 28 20:06 ET

Express News | Outlook Therapeutics Gains Marketing Authorization From European Commission For LYTENAVA To Treat Retina Diseases

BenzingaMay 28 08:10 ET

Express News | Outlook Therapeutics Inc - Strategic Partnership With Cencora (Formerly Amerisourcebergen) to Support Planned Commercial Launches of Lytenava in EU

ReutersMay 28 08:05 ET

Express News | Outlook Therapeutics Inc - Lytenava™ (Bevacizumab Gamma) Receives Ten Years of Market Exclusivity in EU

ReutersMay 28 08:05 ET

Express News | Outlook Therapeutics Inc - Advancing Toward Commercial Launch of Lytenava™ (Bevacizumab Gamma) in EU Expected in Calendar Q1 2025

ReutersMay 28 08:05 ET

Express News | Outlook Therapeutics® Receives European Commission Marketing Authorization for Lytenava™ (Bevacizumab Gamma) for the Treatment of Wet AMD

ReutersMay 28 08:05 ET

Express News | HC Wainwright & Co. Reiterates Buy on Outlook Therapeutics, Maintains $30 Price Target

BenzingaMay 17 10:27 ET

Buy Rating Affirmed for Outlook Therapeutics on Strong EU Prospects and Solid Financial Position

TipRanksMay 17 06:17 ET

Q2 2024 Outlook Therapeutics Inc Earnings Call

Yahoo FinanceMay 17 04:27 ET

Earnings Call Summary | Outlook Therapeutics(OTLK.US) Q2 2024 Earnings Conference

The following is a summary of the Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript:Financial Performance:Outlook Therapeutics recently secured funding through a private placement, ge

moomoo AIMay 16 19:50 ET · Conference Call

Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript

Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 16 14:35 ET

Express News | Outlook Therapeutics Inc - Qtrly Shr Loss $8.01

ReutersMay 15 17:50 ET

Outlook Therapeutics | 10-Q: Quarterly report

SEC announcementMay 15 17:22 ET · Announcements

Express News | Outlook Therapeutics Q2 2024 Adj EPS $(1.55) Misses $(0.85) Estimate

BenzingaMay 15 17:02 ET

Outlook Therapeutics Had Cash and Cash Equivalents of $47.2 M as of March 31>OTLK

Outlook Therapeutics Had Cash and Cash Equivalents of $47.2 M as of March 31>OTLK

Dow JonesMay 15 17:02 ET

Outlook Therapeutics 2Q Loss/Shr $8.01 >OTLK

Outlook Therapeutics 2Q Loss/Shr $8.01 >OTLK

Dow JonesMay 15 17:01 ET

Express News | Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update

ReutersMay 15 17:00 ET

Express News | Outlook Therapeutics Submits Marketing Authorization Application For ONS-5010 In Wet AMD To MHRA

BenzingaMay 13 08:51 ET

Express News | Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (Maa) for Ons-5010 as a Treatment for Wet AMD

ReutersMay 13 08:50 ET

Outlook Therapeutics to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment

GlobeNewswireMay 9 08:45 ET